212 related articles for article (PubMed ID: 29544762)
1. Prognostic Effect of CD20 Expression in Adult B-cell Acute Lymphoblastic Leukemia.
Esteban RE; Christianne B; Alvaro A; Demichelis-Gómez R
Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):361-367. PubMed ID: 29544762
[TBL] [Abstract][Full Text] [Related]
2. Outcome of CD20-positive Adult B-cell Acute Lymphoblastic Leukemia and the Impact of Rituximab Therapy.
Alduailej H; Kanfar S; Bakhit K; Raslan H; Alsaber A; Bashawri L; Aldayel A; Alanezi K
Clin Lymphoma Myeloma Leuk; 2020 Sep; 20(9):e560-e568. PubMed ID: 32600932
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia.
Thomas DA; O'Brien S; Jorgensen JL; Cortes J; Faderl S; Garcia-Manero G; Verstovsek S; Koller C; Pierce S; Huh Y; Wierda W; Keating MJ; Kantarjian HM
Blood; 2009 Jun; 113(25):6330-7. PubMed ID: 18703706
[TBL] [Abstract][Full Text] [Related]
4. Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia.
Maury S; Chevret S; Thomas X; Heim D; Leguay T; Huguet F; Chevallier P; Hunault M; Boissel N; Escoffre-Barbe M; Hess U; Vey N; Pignon JM; Braun T; Marolleau JP; Cahn JY; Chalandon Y; Lhéritier V; Beldjord K; Béné MC; Ifrah N; Dombret H;
N Engl J Med; 2016 Sep; 375(11):1044-53. PubMed ID: 27626518
[TBL] [Abstract][Full Text] [Related]
5. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia.
Thomas DA; O'Brien S; Faderl S; Garcia-Manero G; Ferrajoli A; Wierda W; Ravandi F; Verstovsek S; Jorgensen JL; Bueso-Ramos C; Andreeff M; Pierce S; Garris R; Keating MJ; Cortes J; Kantarjian HM
J Clin Oncol; 2010 Aug; 28(24):3880-9. PubMed ID: 20660823
[TBL] [Abstract][Full Text] [Related]
6. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.
Thomas DA; Faderl S; O'Brien S; Bueso-Ramos C; Cortes J; Garcia-Manero G; Giles FJ; Verstovsek S; Wierda WG; Pierce SA; Shan J; Brandt M; Hagemeister FB; Keating MJ; Cabanillas F; Kantarjian H
Cancer; 2006 Apr; 106(7):1569-80. PubMed ID: 16502413
[TBL] [Abstract][Full Text] [Related]
7. High expression of ID family and IGJ genes signature as predictor of low induction treatment response and worst survival in adult Hispanic patients with B-acute lymphoblastic leukemia.
Cruz-Rodriguez N; Combita AL; Enciso LJ; Quijano SM; Pinzon PL; Lozano OC; Castillo JS; Li L; Bareño J; Cardozo C; Solano J; Herrera MV; Cudris J; Zabaleta J
J Exp Clin Cancer Res; 2016 Apr; 35():64. PubMed ID: 27044543
[TBL] [Abstract][Full Text] [Related]
8. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.
Griffin TC; Weitzman S; Weinstein H; Chang M; Cairo M; Hutchison R; Shiramizu B; Wiley J; Woods D; Barnich M; Gross TG;
Pediatr Blood Cancer; 2009 Feb; 52(2):177-81. PubMed ID: 18816698
[TBL] [Abstract][Full Text] [Related]
9. Cd20 Expression and Effects on Outcome of Relapsed/ Refractory Diffuse Large B Cell Lymphoma after Treatment with Rituximab.
Rasheed AA; Samad A; Raheem A; Hirani SI; Shabbir- Moosajee M
Asian Pac J Cancer Prev; 2018 Feb; 19(2):331-335. PubMed ID: 29479962
[TBL] [Abstract][Full Text] [Related]
10. [Clinical and Prognostic analysis of 43 Children with Mature B-cell Non-Hodgkin's Lymphoma/Acute Lymphoblastic Leukemia].
Guo J; Zhu YP; Gao J; Li Q; Jia CS; Zhou CY; Guo X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):72-9. PubMed ID: 26913397
[TBL] [Abstract][Full Text] [Related]
11. [CD20 Expression in Adult Patients with B-lineage Acute Lymphoblastic Leukemia and Its Prognostic Significance].
Zhou J; Wang J; Liu H; Zheng HF; Ma L; Wang PF; Yan S; Fu CC
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Jun; 23(3):619-22. PubMed ID: 26117004
[TBL] [Abstract][Full Text] [Related]
12. Predictive significance of the cut-off value of CD20 expression in patients with B-cell lymphoma.
Horvat M; Kloboves Prevodnik V; Lavrencak J; Jezersek Novakovic B
Oncol Rep; 2010 Oct; 24(4):1101-7. PubMed ID: 20811695
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of new anti-CD20 monoclonal antibodies versus rituximab for induction therapy of CD20
Luo C; Wu G; Huang X; Ma Y; Zhang Y; Song Q; Xie M; Sun Y; Huang Y; Huang Z; Hou Y; Xu S; Chen J; Li X
Sci Rep; 2021 Feb; 11(1):3255. PubMed ID: 33547368
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial.
Ribera JM; Ortega JJ; Oriol A; Granada I; Hernández-Rivas JM; Parody R; Bethencourt C; Rivas C; Bastida P; del Potro E; González-Valentín ME; Moreno MJ; Besalduch J; Fernández-Calvo J; Tormo M; Arias J; Molinés A; Sanz MA; Maldonado J; Millá F; Feliu E; San Miguel JF;
Haematologica; 2002 Feb; 87(2):154-66. PubMed ID: 11836166
[TBL] [Abstract][Full Text] [Related]
15. Bone marrow infiltration of CD20-negative follicular lymphoma after rituximab therapy: a histological mimicker of hematogones and B-cell acute lymphoblastic leukemia/lymphoma.
Matsuda I; Hirota S
Int J Clin Exp Pathol; 2015; 8(8):9737-41. PubMed ID: 26464748
[TBL] [Abstract][Full Text] [Related]
16. Rituximab plus multiagent chemotherapy for newly diagnosed CD20-positive acute lymphoblastic leukemia: a prospective phase II study.
Baek DW; Park HS; Sohn SK; Kim DY; Kim I; Ahn JS; Do YR; Lee SR; Eom HS; Lee WS; Kim SH; Lee HS; Lee YJ; Moon JH; Lee JH;
Korean J Intern Med; 2023 Sep; 38(5):734-746. PubMed ID: 37334511
[TBL] [Abstract][Full Text] [Related]
17. Economic evaluation of rituximab in addition to standard of care chemotherapy for adult patients with acute lymphoblastic leukemia.
Nam J; Milenkovski R; Yunger S; Geirnaert M; Paulson K; Seftel M
J Med Econ; 2018 Jan; 21(1):47-59. PubMed ID: 28837377
[TBL] [Abstract][Full Text] [Related]
18. [Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China--a multi-center randomized trail].
Lin TY; Zhang HY; Huang Y; Guan ZZ; Shen T; Shi YK; Zhu J; Ke XY; Wang HQ; Shen ZX; Yu SY; Liu T; Shi XL
Ai Zheng; 2005 Dec; 24(12):1421-6. PubMed ID: 16351785
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and prognostic factors of imatinib plus CALLG2008 protocol in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
Lou Y; Ma Y; Li C; Suo S; Tong H; Qian W; Mai W; Meng H; Yu W; Mao L; Wei J; Xu W; Jin J
Front Med; 2017 Jun; 11(2):229-238. PubMed ID: 28349299
[TBL] [Abstract][Full Text] [Related]
20. CD20 expression in B-cell precursor acute lymphoblastic leukemia is common in Mexican patients and lacks a prognostic value.
Solano-Genesta M; Tarín-Arzaga L; Velasco-Ruiz I; Lutz-Presno JA; González-Llano O; Mancías-Guerra C; Rodríguez-Romo L; Ruiz-Delgado GJ; Ruiz-Argüelles GJ; Jaime-Pérez JC; Gómez-Almaguer D
Hematology; 2012 Mar; 17(2):66-70. PubMed ID: 22664043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
